PDCD1 and neoplasm: Nielsen et al. [60] demonstrated that lorlatinib could modulate tumor-promoting neutrophil functions and improve the response to an anti-PD-1 antibody due to more activated CD8+ T cell infiltration in pancreatic the TME.